Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22363311 | 1.00 | TLR2 (0.51) | TLR2EPHX2CSNK1ECNR2SIGMAR1 | |
| SCHEMBL11702193 | 1.00 | TLR2 (0.51) | TLR2EPHX2CSNK1ECNR2SIGMAR1 | |
| SCHEMBL7065867 | 1.00 | TLR2 (0.51) | TLR2EPHX2CSNK1ECNR2SIGMAR1 | |
| SCHEMBL18741386 | 1.00 | TLR2 (0.51) | TLR2EPHX2CSNK1ECNR2SIGMAR1 | |
| SCHEMBL11349595 | 1.00 | TLR2 (0.51) | TLR2EPHX2CSNK1ECNR2SIGMAR1 | |
| SCHEMBL23634016 | 1.00 | TLR2 (0.51) | TLR2EPHX2CSNK1ECNR2SIGMAR1 | |
| SCHEMBL1091520 | 1.00 | TLR2 (0.51) | TLR2EPHX2CSNK1ECNR2SIGMAR1 | |
| SCHEMBL1090569 | 1.00 | TLR2 (0.51) | TLR2EPHX2CSNK1ECNR2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL11489605 | 0.98 | TLR2 (0.50) | TLR2EPHX2CSNK1ECNR2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1485808 | 0.98 | TLR2 (0.50) | TLR2EPHX2CSNK1ECNR2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844032-B2 | Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | TLR2 3034/4885EPHX2 4188/4885CSNK1E 373/4885 |
| US-10844032-B2 | Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors | MCL1, BCL2L1, BCLAF1 | TLR2 2491/4885EPHX2 4485/4885CSNK1E 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.